Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEATRICE: Adjuvant Bevacizumab in Triple Negative Breast Cancer
NCT00528567Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2007
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
- Countries
- 40
01
Overview
A Phase 3 trial of bevacizumab in triple-negative breast cancer (TNBC), sponsored by Roche. Started Dec 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00528567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00528567.